The following drugs were administered intracerebrally in the study: (a)
muscimol hydrobromide (0.5 μl of 2 μg/μl solution; Sigma, USA), muscimol being a GABA mimetic
28 (link), (b) (2 R)-amino-5-phosphonopentanoate (AP5; 0.5 μl of 5 μg/μl solution; Sigma, USA) which is an antagonist at the glutamate NMDA receptors
68 (link),89 (link),90 (link), (c)
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX; 0.5 μl of 10 μg/μl, 20 μg/μl or 40 μg/μl solution; Tocris, USA) which is an antagonist at glutamate AMPA receptor
39 (link),92 (link), and (d)
lidocaine hydrochloride (0.5 μl/site of 4% w/v; Sigma, USA), a local anesthetic
50 (link). The drugs were prepared in 0.5% Alcian blue dye in saline (Sigma, USA) which also acted as vehicle in control experiments. The drugs, (a) through (c), were used in experiments involving microinjection into the MS region. Intraseptal microinjections were made at one given site only, while, in comparison, lidocaine was microinjected bilaterally into the RVM.
Functionally, intraseptal microinjection of the fore-mentioned drugs at the selected concentration attenuates theta rhythmic septo- hippocampal activation
28 (link),68 (link),89 (link)–91 (link). The highest concentration of NBQX used in this study is also known to strongly attenuate afferent stimulation-evoked putative AMPA current in medial septal neurons
39 (link).
Ariffin M.Z., Ibrahim K.M., Lee A.T., Lee R.Z., Poon S.Y., Thong H.K., Liu E.H., Low C.M, & Khanna S. (2018). Forebrain medial septum sustains experimental neuropathic pain. Scientific Reports, 8, 11892.